U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07106671) titled 'A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma' on July 30.

Brief Summary: This is a prospective Phase II study evaluating Siltuximab for CRS and ICANS after CAR-T infusion in multiple myeloma patients.

Study Start Date: Aug. 10

Study Type: INTERVENTIONAL

Condition: CRS - Cytokine Release Syndrome Myeloma

Intervention: DRUG: Siltuximab

Siltuximab 11mg/kg

Recruitment Status: RECRUITING

Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Disclaimer: Curated by HT Syndication....